John A. Orwin - 15 May 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
Director
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
15 May 2025
Transactions value $
$0
Form type
4
Filing time
16 May 2025, 19:00:16 UTC
Previous filing
07 Jan 2025
Next filing
17 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Orwin John A Director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO /s/ Elizabeth E. Reed, Attorney-in-Fact 16 May 2025 0001477384

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVTX Common Stock Award $0 +6,500 +22.51% $0 35,375 15 May 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TVTX Stock option (right to buy) Award $0 +19,500 $0 19,500 15 May 2025 Common Stock 19,500 $21.15 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
F2 The equity award vests over a one year period.